Isabelle Fleury

5.8k total citations
47 papers, 495 citations indexed

About

Isabelle Fleury is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Isabelle Fleury has authored 47 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 18 papers in Genetics. Recurrent topics in Isabelle Fleury's work include Lymphoma Diagnosis and Treatment (29 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Isabelle Fleury is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Isabelle Fleury collaborates with scholars based in Canada, United States and Germany. Isabelle Fleury's co-authors include Daniel Sinnett, Maja Krajinović, Mélanie Primeau, Edmund K. Waller, Joseph P. McGuirk, Damian Labuda, Patrick Beaulieu, Luigina Mollica, Peter Borchmann and Denis‐Claude Roy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Isabelle Fleury

42 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabelle Fleury Canada 12 235 232 121 97 71 47 495
G.A. Amos Burke United Kingdom 13 221 0.9× 282 1.2× 79 0.7× 110 1.1× 141 2.0× 37 601
Yi‐Bin Chen United States 9 172 0.7× 126 0.5× 45 0.4× 58 0.6× 34 0.5× 12 308
Michele Pizzuti Italy 9 108 0.5× 121 0.5× 103 0.9× 57 0.6× 19 0.3× 15 333
Guenter Henze Germany 13 133 0.6× 119 0.5× 52 0.4× 81 0.8× 116 1.6× 34 525
Nadia Khan United States 11 151 0.6× 202 0.9× 115 1.0× 48 0.5× 83 1.2× 37 431
Susana Esteves Portugal 11 133 0.6× 55 0.2× 87 0.7× 25 0.3× 83 1.2× 49 442
Maaike de Bie Netherlands 9 86 0.4× 103 0.4× 54 0.4× 42 0.4× 56 0.8× 17 321
Lynda M. Cristiano United States 9 108 0.5× 165 0.7× 40 0.3× 25 0.3× 66 0.9× 19 541
R Hoyt Australia 10 89 0.4× 114 0.5× 90 0.7× 44 0.5× 29 0.4× 13 304
Arun K. Singavi United States 6 242 1.0× 76 0.3× 60 0.5× 19 0.2× 26 0.4× 14 350

Countries citing papers authored by Isabelle Fleury

Since Specialization
Citations

This map shows the geographic impact of Isabelle Fleury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Fleury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Fleury more than expected).

Fields of papers citing papers by Isabelle Fleury

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Fleury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Fleury. The network helps show where Isabelle Fleury may publish in the future.

Co-authorship network of co-authors of Isabelle Fleury

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Fleury. A scholar is included among the top collaborators of Isabelle Fleury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Fleury. Isabelle Fleury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bartlett, Nancy L., Uwe Hahn, Won Seog Kim, et al.. (2025). Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(9). 1061–1072. 7 indexed citations
2.
3.
Lachance, Silvy, et al.. (2024). Real-world barriers to CAR-T access: A Canadian referral center perspective.. Journal of Clinical Oncology. 42(16_suppl). e19002–e19002. 1 indexed citations
4.
5.
Kim, Jeong‐Ah, Uwe Hahn, Won-Seog Kim, et al.. (2024). Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.. Journal of Clinical Oncology. 42(17_suppl). LBA7005–LBA7005. 3 indexed citations
6.
Lachaîne, Jean, et al.. (2023). Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Current Oncology. 30(5). 4483–4498. 9 indexed citations
7.
8.
Nowakowski, Grzegorz S., Dok Hyun Yoon, Anthea Peters, et al.. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research. 28(18). 4003–4017. 16 indexed citations
9.
Lachance, Silvy, Philippe Bouchard, Imran Ahmad, et al.. (2022). Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy. 29(1). 34.e1–34.e7. 7 indexed citations
10.
Ahmad, Imran, Jean‐Sébastien Delisle, Thomas Kiss, et al.. (2021). Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. Transplantation and Cellular Therapy. 28(3). 145–151. 3 indexed citations
11.
Jaeger, Ulrich, Nina Worel, Joseph P. McGuirk, et al.. (2019). Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 5325–5325. 17 indexed citations
12.
Ahmad, Imran, Nadia M. Bambace, Léa Bernard, et al.. (2019). Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research. 79. 75–80. 8 indexed citations
13.
Ahmad, Imran, Nadia M. Bambace, Léa Bernard, et al.. (2019). Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biology of Blood and Marrow Transplantation. 26(1). 157–161. 14 indexed citations
14.
15.
Pavic, Michel, et al.. (2017). Case Report of Aggressive T-Cell Large Granular Lymphocytic Leukemia. Blood. 130. 5189–5189. 1 indexed citations
16.
17.
Fleury, Isabelle, Sylvie Chevret, Michael Pfreundschuh, et al.. (2015). Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Annals of Oncology. 27(3). 390–397. 49 indexed citations
18.
Lefort, François, et al.. (2014). Pathogenicity of entomopathogenic fungi to the green peach aphid Myzus persicae Sulzer (Aphididae) and the European tarnished bug Lygus rugulipennis Poppius (Miridae).. Egyptian Journal of Biological Pest Control. 24(2). 379–386. 5 indexed citations
19.
Fleury, Isabelle, Sandy Amorim, Nicolas Mounier, et al.. (2014). Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. Leukemia & lymphoma. 56(7). 2025–2031. 4 indexed citations
20.
Fleury, Isabelle, Mélanie Primeau, Irina Costea, et al.. (2004). Polymorphisms in Genes Involved in the Corticosteroid Response and the Outcome of Childhood Acute Lymphoblastic Leukemia. PubMed. 4(5). 331–341. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.A. Amos Burke Breakdown of academic impact, for papers by Yi‐Bin Chen Breakdown of academic impact, for papers by Michele Pizzuti Breakdown of academic impact, for papers by Guenter Henze Breakdown of academic impact, for papers by Nadia Khan Breakdown of academic impact, for papers by Susana Esteves Breakdown of academic impact, for papers by Maaike de Bie Breakdown of academic impact, for papers by Lynda M. Cristiano Breakdown of academic impact, for papers by R Hoyt Breakdown of academic impact, for papers by Arun K. Singavi
Rankless by CCL
2026